Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T.
Marchetti M, et al.
Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.
Leukemia. 2017.
PMID: 27740634
Free article.